List of Obredon drug patents

Obredon is owned by Sovereign Pharms.

Obredon contains Guaifenesin; Hydrocodone Bitartrate.

Obredon has a total of 3 drug patents out of which 0 drug patents have expired.

Obredon was authorised for market use on 14 November, 2014.

Obredon is available in solution;oral dosage forms.

Obredon can be used as a method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or increases the auc (0-inf) by at least 1.4.

The generics of Obredon are possible to be released after 13 November, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9549907 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

US9808431 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

US10105324 SOVEREIGN PHARMS Immediate release oral guaifenesin solution
Nov, 2035

(12 years from now)

Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 14 November, 2014

Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or increases the auc (0-inf) by at least 1.4

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic